Form 4: Apellis Pharmaceuticals CTO Granted Significant Stock Option Award

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, was granted 82,500 stock options with an exercise price of $19.39, vesting over two years.

Summary

• Nur Nicholson, the Chief Technical Officer of Apellis Pharmaceuticals, Inc. (APLS), received a stock option award.
• The award consists of 82,500 stock options, granted on June 9, 2025.
• The exercise price for these options is $19.39 per share.
• The options have an expiration date of June 9, 2035.
• The options will vest over a two-year period, with 50% vesting on the one-year anniversary and the remaining 50% on the two-year anniversary of the grant date, contingent upon continued service.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's interests with shareholders and aids in executive retention. However, it is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of 82,500 stock options to the Chief Technical Officer aligns management's incentives with shareholder value creation.
• The two-year vesting schedule encourages long-term commitment and retention of key executive talent within the company.

Future Outlook

The stock options granted to the Chief Technical Officer are subject to a two-year vesting schedule, contingent upon continued service, indicating an expectation of the executive's ongoing contribution to the company's future performance.

Industry Context

The granting of stock options to key executives like the Chief Technical Officer is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize talent, aligning their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• Granting stock options as part of executive compensation is a common practice across the pharmaceutical and biotech sectors, comparable to compensation structures at companies like Biogen, Vertex Pharmaceuticals, or Moderna, which frequently use equity awards to incentivize leadership.
• The vesting schedule of two years is within typical industry ranges, often seen in similar grants at peer companies, balancing immediate incentive with long-term retention.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased long-term value creation due to aligned executive incentives.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent, potentially boosting morale.

Next Steps

• Continued service of Nur Nicholson to meet the vesting conditions for the stock options.
• Potential exercise of the vested stock options by Nur Nicholson at or before their expiration date.

Key Dates

Recommendation

Keywords

Apellis Pharmaceuticals, APLS, stock option, insider transaction, Form 4, Nur Nicholson, Chief Technical Officer, equity compensation